Soutrik Banerjee, PhD

Eli lilly and company
Indianapolis, Indiana, United States

Disclosure information not submitted.

Presentation(s):

• SAT-679 - 12-month Real-World Weight Loss with Tirzepatide among Individuals with Obesity/Overweight who switched from Semaglutide

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-680 - BMI Category Shifts following Tirzepatide Persistent Use among Adults with Overweight or Obesity without Diabetes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-681 - Tirzepatide Persistence and Adherence Post Supply Shortage by Payer Type among Individuals with Obesity/Overweight and without Diabetes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT